公开(公告)号：US20100168197A1

公开(公告)日：2010-07-01

申请号：US12528987

申请日：2008-02-27

Applicant: Naresh Kumar ,  Jaskiran Kaur ,  Shelly Aeron ,  Abhijit Ray ,  Suman Gupta ,  Shivani Malhotra ,  Raj Kumar Shirumalla

Inventor： Naresh Kumar ,  Jaskiran Kaur ,  Shelly Aeron ,  Abhijit Ray ,  Suman Gupta ,  Shivani Malhotra ,  Raj Kumar Shirumalla

IPC: A61K31/4164 ,  C07D233/54

CPC classification number: C07D235/08 ,  C07D233/54 ,  C07D409/06

Abstract: This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

Abstract translation: 本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。 本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。

公开(公告)号：US20100144801A1

公开(公告)日：2010-06-10

申请号：US12443838

申请日：2007-10-02

Applicant: Naresh Kumar ,  Jaskiran Kaur ,  Abhijit Ray ,  Suman Gupta ,  Shivani Malhotra ,  Rajkumar Shirumalla

Inventor： Naresh Kumar ,  Jaskiran Kaur ,  Abhijit Ray ,  Suman Gupta ,  Shivani Malhotra ,  Rajkumar Shirumalla

IPC: A61K31/44 ,  C07D213/55 ,  C07D233/54 ,  A61K31/4164 ,  A61P11/00 ,  A61P13/00 ,  A61P1/00 ,  A61P3/00

CPC classification number: C07D233/64 ,  C07D211/70 ,  C07D213/30

Abstract: The present invention generally relates to muscarinic receptor antagonists of formula I, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Formula (I) wherein Het: is heterocyclyl or heteroaryl X: O, S or NR1 and the other substituents are defined as in the claims.

Abstract translation: 本发明一般涉及式I的毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。 本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。 式（I）其中Het：是杂环基或杂芳基X：O，S或NR1，其它取代基如权利要求中所定义。

公开(公告)号：US20190197589A1

公开(公告)日：2019-06-27

申请号：US15855035

申请日：2017-12-27

Applicant: Harpal Singh ,  Gursneh Nanak Kaur ,  Vijit Nanak Singh ,  Jaskiran Kaur

Inventor： Harpal Singh ,  Gursneh Nanak Kaur ,  Vijit Nanak Singh ,  Jaskiran Kaur

IPC: G06Q30/02 ,  G06Q20/02 ,  G06Q20/32 ,  G06N5/02 ,  G06F9/44

CPC classification number: G06Q30/0279 ,  G06F9/451 ,  G06N5/02 ,  G06Q20/027 ,  G06Q20/322

Abstract: Disclosed is a method of facilitating operation of an entity. The method may include receiving, using a communication device, an event data corresponding to an event associated with the entity. Further, the method may include receiving, using the communication device, user data from two or more mobile devices associated with two or more users. Yet further, the method may include identifying, using a processing device, one or more users based on each of the event data and the user data. Further, the method may include transmitting, using the communication device, one or more notifications to the one or more mobile devices based on the identifying. Moreover, the method may include receiving, using the communication device, an indication of a donation from the one or more mobile devices. The donation may be associated with the event.

公开(公告)号：US20100222393A1

公开(公告)日：2010-09-02

申请号：US12159505

申请日：2006-12-21

Applicant: Naresh Kumar ,  Jaskiran Kaur ,  Venkata P. Palle ,  Beenu Bhatt ,  Shelly Jindal ,  Anita Chugh ,  Suman Gupta ,  Abhijit Ray ,  Shivani Malhotra ,  Raj Kumar Shirumalla

Inventor： Naresh Kumar ,  Jaskiran Kaur ,  Venkata P. Palle ,  Beenu Bhatt ,  Shelly Jindal ,  Anita Chugh ,  Suman Gupta ,  Abhijit Ray ,  Shivani Malhotra ,  Raj Kumar Shirumalla

IPC: A61K31/4439 ,  C07D233/54 ,  A61K31/4164 ,  C07D401/02 ,  A61P11/00 ,  A61P13/00 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07D233/54 ,  C07D233/14 ,  C07D233/56 ,  C07D233/64 ,  C07D401/12

Abstract: Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy; X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom; Het is heterocyclyl or heteroaryl; n is an integer from 1 to 6; are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and 4 i gastrointestinal systems mediated through muscarinic receptors.

Abstract translation: 式（I）的化合物，当G为-OH时，当G为-O时，表示单键; R 1和R 2独立地选自氢，烷基，烯基，炔基，芳烷基，环烷基，芳基，杂芳基，杂环基，杂环基烷基或杂芳基烷基; R3选自氢，羟基，烷氧基，烯氧基或炔氧基; X选自氧，-NH，-NR（其中R是烷基，烯基，烯基，炔基或芳基），硫或无原子; Het是杂环基或杂芳基; n是1至6的整数; 是毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，尿和4I胃肠系统的各种疾病，以及其它用途。